GO:0007093 mitotic cell cycle checkpoint signaling: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007093 mitotic cell cycle checkpoint signaling is a biological process that prevents mitotic progression until chromosome replication and segregation are accurate.
• Core checkpoint modules include the DNA damage response (ATM/ATR-CHEK1/2), the spindle assembly checkpoint (SAC; MAD1L1, MAD2L1, BUB1B, BUB3), and mitotic exit regulators.
• Checkpoint dysregulation is a hallmark of cancer and contributes to chromosomal instability, therapy resistance, and familial cancer predisposition.
• The G2/M checkpoint is a major target for synthetic lethality and radiosensitization in melanoma and other tumors.
• Prolonged checkpoint arrest requires sustained DNA damage signaling and an active SAC, as shown in yeast models.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of checkpoint genes in isogenic backgrounds.
Description
GO:0007093 mitotic cell cycle checkpoint signaling is the signaling process that ensures accurate chromosome replication and segregation by preventing progression through a mitotic cell cycle until conditions are suitable for the cell to proceed to the next stage. This process is central to genome maintenance and is executed by surveillance pathways that monitor DNA integrity, replication completion, and spindle attachment to kinetochores. Because checkpoint signaling coordinates cell cycle transitions with repair and segregation, its dysfunction is directly linked to aneuploidy, chromosomal instability, and tumorigenesis. In cancer biology, checkpoint kinases such as ATM, ATR, CHEK1, and CHEK2 are intensively studied as therapeutic targets, and the G2/M checkpoint is exploited for synthetic lethality and radiosensitization. In model organisms such as Saccharomyces cerevisiae, checkpoint regulators control mitotic exit and adaptation to prolonged arrest, providing mechanistic insight conserved in human cells. For researchers, GO:0007093 provides a precise ontology anchor for interpreting functional genomics screens, phosphoproteomics, and CRISPR perturbation experiments aimed at dissecting checkpoint control.
mitotic cell cycle checkpoint signaling At A Glance
| GO ID | GO:0007093 |
|---|---|
| GO term | mitotic cell cycle checkpoint signaling |
| Ontology | biological_process |
| Synonym | mitotic cell cycle checkpoint; mitotic checkpoint; signal transduction involved in mitotic cell cycle checkpoint; signal transduction involved in mitotic cell cycle G1/S checkpoint; signal transduction involved in mitotic G2/M transition checkpoint |
| Major function | Prevents progression through a mitotic cell cycle until conditions are suitable for the cell to proceed to the next stage |
| Biological context | DNA damage response, replication stress, spindle assembly checkpoint, mitotic exit control |
| Disease relevance | Cancer, chromosomal instability, familial cancer predisposition, therapy resistance |
| Therapeutic focus | G2/M checkpoint inhibitors, radiosensitization, synthetic lethality |
| Model systems | Human cell lines, Saccharomyces cerevisiae, mouse models |
What Is GO:0007093?
In our own words, GO:0007093 mitotic cell cycle checkpoint signaling describes the signal transduction events that delay or arrest the mitotic cell cycle when replication or segregation is incomplete or damaged, thereby preventing the cell from advancing to the next stage until conditions are suitable. This includes checkpoint signaling at the G1/S, G2/M, and metaphase-to-anaphase transitions, as well as the signaling that maintains arrest and coordinates recovery or adaptation.
Why Is mitotic cell cycle checkpoint signaling Important in Cell Biology?
Mitotic cell cycle checkpoint signaling is essential because it safeguards genome integrity by coupling cell cycle progression to the completion of DNA replication and accurate chromosome segregation. When checkpoint signaling fails, cells accumulate chromosomal aberrations and aneuploidy, which are hallmarks of cancer and drivers of tumor evolution. Checkpoint pathways also determine sensitivity to DNA-damaging agents and radiation, making them central to oncology drug development and precision medicine. In familial cancer syndromes, inherited defects in checkpoint components can predispose to malignancy, underscoring their role in disease etiology. Beyond cancer, checkpoint signaling influences tissue homeostasis, aging, and responses to replication stress, making it a broad biomedical priority.
• Prevents aneuploidy by delaying mitosis until chromosomes are properly attached and aligned.
• Coordinates DNA repair with cell cycle transitions through ATM/ATR-CHEK1/2 signaling.
• Dysregulation is a hallmark of cancer and contributes to chromosomal instability.
• Inherited checkpoint defects are linked to familial cancer predisposition.
• G2/M checkpoint inhibition sensitizes tumors to radiation and DNA-damaging chemotherapy.
• Synthetic lethal strategies exploit checkpoint vulnerabilities in melanoma and other cancers.
• Prolonged arrest requires sustained DNA damage signaling and an active spindle assembly checkpoint.
• Yeast models reveal conserved mechanisms of mitotic exit control and checkpoint adaptation.
• Checkpoint kinases are actionable drug targets with ongoing clinical development.
• CRISPR screens identify checkpoint dependencies and resistance mechanisms.
What Happens During mitotic cell cycle checkpoint signaling?
DNA damage and replication stress sensing
In simple terms: The cell first detects whether its DNA is damaged or replication is incomplete.
Checkpoint signaling is initiated by sensor kinases ATM and ATR, which are recruited to DNA lesions and replication protein A-coated single-stranded DNA, respectively. These sensors activate downstream effector kinases CHEK1 and CHEK2, which amplify and transmit the checkpoint signal to cell cycle machinery. In yeast, the DNA damage checkpoint maintains arrest through sustained signaling, and adaptation requires downregulation of the damage signal. This sensing step is critical for preventing entry into mitosis with unrepaired DNA.
G2/M transition arrest
In simple terms: The cell pauses before mitosis to allow repair or completion of replication.
Activated CHEK1 and CHEK2 phosphorylate CDC25 phosphatases, leading to their inhibition or degradation, which prevents activation of CDK1-cyclin B and blocks entry into mitosis. This G2/M checkpoint arrest provides time for DNA repair and is a key determinant of sensitivity to radiation and DNA-damaging agents. In melanoma, targeting the G2-M checkpoint induces synthetic lethality in tumor cells with high replication stress. The duration of arrest depends on the persistence of the upstream damage signal.
Spindle assembly checkpoint (SAC) activation
In simple terms: The cell checks that every chromosome is properly attached to the spindle before separating them.
The SAC monitors kinetochore-microtubule attachments and prevents anaphase onset until all chromosomes are bi-oriented. Core SAC proteins including MAD1L1, MAD2L1, BUB1B, and BUB3 assemble at unattached kinetochores and generate a diffusible inhibitor of the anaphase-promoting complex/cyclosome (APC/C). This inhibition prevents separase activation and sister chromatid separation until attachments are correct. SAC dysfunction leads to chromosome missegregation and aneuploidy, which are common in cancer.
Mitotic exit and adaptation
In simple terms: After chromosomes are segregated, the cell turns off the checkpoint and exits mitosis.
Once all chromosomes are properly attached and aligned, the SAC is silenced, allowing APC/C activation and progression to anaphase. In Saccharomyces cerevisiae, mitotic exit is controlled by the mitotic exit network (MEN) and is coordinated with checkpoint silencing. Prolonged arrest in response to persistent DNA damage requires maintenance of both DNA damage signaling and the SAC, and cells can eventually adapt and resume cycling. This adaptation process is relevant to cancer therapy resistance and relapse.
Key Genes Involved in GO:0007093 mitotic cell cycle checkpoint signaling
The following genes and proteins are central to mitotic cell cycle checkpoint signaling and are frequently studied in cancer and model organism research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ATM | DNA damage sensor kinase activating checkpoint signaling | Ataxia-telangiectasia and cancer predisposition; radiosensitivity studies |
| ATR | Replication stress sensor kinase | Chemotherapy and radiation response; synthetic lethality |
| CHEK1 | Effector kinase downstream of ATR | G2/M checkpoint inhibitor target; radiosensitization |
| CHEK2 | Effector kinase downstream of ATM | Familial cancer risk; DNA damage response |
| CDC25A | Phosphatase regulating CDK1 activity | Cell cycle arrest and checkpoint recovery |
| CDC25C | Phosphatase regulating mitotic entry | G2/M transition control |
| CDK1 | Cyclin-dependent kinase driving mitosis | Target of checkpoint arrest; drug target |
| CCNB1 | Cyclin B1, partner of CDK1 | Mitotic entry and checkpoint control |
| MAD1L1 | Spindle assembly checkpoint protein | Kinetochore signaling; aneuploidy |
| MAD2L1 | Spindle assembly checkpoint protein | APC/C inhibition; cancer |
| BUB1B | Spindle assembly checkpoint kinase | Chromosomal instability; familial cancer |
| BUB3 | Spindle assembly checkpoint protein | Kinetochore recruitment; SAC function |
| TTK | Spindle assembly checkpoint kinase | Aneuploidy and cancer therapy |
| PLK1 | Polo-like kinase regulating mitosis | Checkpoint recovery and drug target |
| AURKA | Aurora kinase A regulating spindle assembly | Mitotic checkpoint and cancer |
| AURKB | Aurora kinase B regulating chromosome segregation | Chromosomal instability |
| TP53 | Tumor suppressor integrating checkpoint signals | Cell cycle arrest and apoptosis |
| WEE1 | Kinase inhibiting CDK1 | G2/M checkpoint target; radiosensitization |
How Is mitotic cell cycle checkpoint signaling Regulated?
Mitotic cell cycle checkpoint signaling is regulated by the intensity and duration of upstream DNA damage and replication stress signals, which determine whether cells arrest transiently or undergo prolonged arrest and adaptation. Phosphorylation cascades involving ATM/ATR-CHEK1/2 and CDC25 phosphatases control CDK1 activity and the G2/M transition. The spindle assembly checkpoint is regulated by kinetochore recruitment of MAD1L1, MAD2L1, BUB1B, and BUB3, and by the rate of APC/C inhibition. In yeast, mitotic exit is coordinated by the MEN and checkpoint silencing. Additionally, checkpoint strength can be modulated by the duration of DNA damage signaling, as prolonged arrest requires maintained signaling.
mitotic cell cycle checkpoint signaling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CHEK2 | Familial breast and other cancers; DNA damage response | Knockout and point mutation cell lines; isogenic pairs |
| BUB1B | Chromosomal instability; familial cancer predisposition | Knockout and knock-in models; SAC assays |
| TP53 | Li-Fraumeni syndrome; cell cycle checkpoint defects | Knockout and point mutation models; radiation response |
| WEE1 | Cancer therapy resistance; G2/M checkpoint | Knockout and overexpression; radiosensitization studies |
| MAD2L1 | Aneuploidy and cancer | Knockout and tagged knock-in; live-cell imaging |
Cancer and chromosomal instability
Dysregulation of mitotic cell cycle checkpoint signaling is a hallmark of cancer, leading to chromosomal instability, aneuploidy, and tumor progression. Mutations in checkpoint genes such as CHEK2 and BUB1B are associated with increased cancer risk and familial predisposition. Loss of checkpoint control allows cells to proliferate despite DNA damage, promoting mutagenesis and therapy resistance.
Familial cancer predisposition
Inherited defects in mitotic checkpoint components, including BUB1B and CHEK2, have been linked to familial cancer syndromes characterized by chromosomal instability. These germline mutations impair the ability to delay mitosis until chromosomes are properly segregated, increasing susceptibility to malignancies.
Therapy resistance and radiosensitization
The G2/M checkpoint is a critical determinant of sensitivity to radiation and DNA-damaging chemotherapy. Inhibitors of checkpoint kinases such as CHEK1 and WEE1 abrogate G2/M arrest, forcing cells with damaged DNA into mitosis and inducing mitotic catastrophe. This strategy is being tested in melanoma and other cancers with high replication stress.
Synthetic lethality in melanoma
Targeting the G2-M checkpoint induces synthetic lethality in melanoma cells with specific genetic backgrounds, offering a precision medicine approach. This exploits the reliance of tumor cells on checkpoint signaling to survive replication stress and DNA damage.
From mitotic cell cycle checkpoint signaling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CHEK2 abrogate G2/M arrest? | CHEK2 knockout cell line |
| Does a cancer-associated BUB1B mutation impair SAC? | BUB1B point mutation knock-in |
| Can WEE1 overexpression confer radioresistance? | WEE1 overexpression model |
| Where does MAD2L1 localize during mitosis? | MAD2L1 tagged knock-in with live imaging |
| Does ATR inhibition cause synthetic lethality? | ATR knockout or inhibitor-treated isogenic lines |
| How does prolonged arrest affect adaptation? | Yeast checkpoint mutants and time-lapse microscopy |
How to Study the mitotic cell cycle checkpoint signaling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Live-cell imaging | Kinetochore recruitment and SAC silencing kinetics | Checkpoint dynamics in single cells |
| Phosphoproteomics | ATM/ATR/CHEK substrate phosphorylation | Mapping DNA damage signaling networks |
| CRISPR knockout screens | Gene dependencies and synthetic lethality | Identifying checkpoint vulnerabilities |
| Flow cytometry | Cell cycle distribution and mitotic index | Quantifying G2/M arrest |
| Immunofluorescence | Localization of checkpoint proteins | Kinetochore and spindle assembly |
| Yeast genetics | Checkpoint adaptation and mitotic exit | Mechanistic studies of prolonged arrest |
| RNA-seq | Transcriptional responses to checkpoint activation | Pathway analysis and biomarker discovery |
| Western blot | Phosphorylation status of checkpoint kinases | Target engagement and pathway activation |
Live-cell imaging of checkpoint dynamics
Live-cell imaging using fluorescently tagged checkpoint proteins such as MAD2L1 and BUB1B allows real-time monitoring of kinetochore recruitment and SAC silencing. This method reveals the kinetics of checkpoint activation and adaptation in single cells.
Phosphoproteomics of DNA damage signaling
Phosphoproteomic profiling after DNA damage identifies substrates of ATM, ATR, CHEK1, and CHEK2, mapping the signaling network downstream of checkpoint activation. This approach can uncover biomarkers of checkpoint activity and drug response.
CRISPR screens for checkpoint dependencies
Genome-wide CRISPR knockout screens identify genes required for checkpoint function and survival under DNA-damaging conditions. These screens can reveal synthetic lethal interactions with checkpoint inhibitors.
Flow cytometry and mitotic index analysis
Flow cytometry with phospho-histone H3 and DNA content staining quantifies G2/M arrest and mitotic entry after checkpoint activation or inhibition. This is a standard readout for checkpoint function and drug efficacy.
How CRISPR Can Be Used to Study GO:0007093 mitotic cell cycle checkpoint signaling
Knockout
CRISPR knockout of checkpoint genes such as CHEK1, CHEK2, or BUB1B abolishes checkpoint signaling, causing cells to enter mitosis with damaged DNA or misaligned chromosomes. These models are used to test synthetic lethality and radiosensitization.
Point Mutation
Knock-in of cancer-associated point mutations in checkpoint genes, such as BUB1B or CHEK2 variants, allows functional assessment of specific alleles in isogenic backgrounds. This approach distinguishes loss-of-function from dominant-negative or gain-of-function effects.
Knock-in
Tagged knock-in of checkpoint proteins with fluorescent or affinity tags enables live-cell imaging and proteomic analysis of kinetochore dynamics. This provides spatial and temporal resolution of checkpoint signaling.
Overexpression
Overexpression of checkpoint kinases such as WEE1 or CHEK1 can induce cell cycle arrest and confer resistance to DNA-damaging agents. These models are used to study checkpoint adaptation and drug resistance mechanisms.
How EDITGENE Supports mitotic cell cycle checkpoint signaling Research
Researchers studying mitotic cell cycle checkpoint signaling-related genes often need to determine whether a candidate gene is causally involved in checkpoint control, chromosomal stability, or therapy response. EDITGENE provides publication-ready CRISPR models and screening services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for mitotic cell cycle checkpoint signaling research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NBN Knockout HEK293 Cell Line | EDJ-KQ3180 | Human | 4683 | Details Get a Quote |
| NBN Knockout A-549 Cell Line | EDJ-KQ24607 | Human | 4683 | Details Get a Quote |
| NBN Knockout HCT 116 Cell Line | EDJ-KQ24608 | Human | 4683 | Details Get a Quote |
| NBN Knockout HeLa Cell Line | EDJ-KQ24609 | Human | 4683 | Details Get a Quote |
| NBN (p.A127=) Point Mutation in HAP1 Cell Line | EDC03560 | Human | 4683 | Details Get a Quote |
Displaying Records 1 To 5 Of 5 Records
Frequently Asked Questions About mitotic cell cycle checkpoint signaling
What is GO:0007093 mitotic cell cycle checkpoint signaling?
It is the biological process that ensures accurate chromosome replication and segregation by preventing progression through a mitotic cell cycle until conditions are suitable.
What genes are involved in mitotic cell cycle checkpoint signaling?
Key genes include ATM, ATR, CHEK1, CHEK2, CDC25A, CDC25C, CDK1, CCNB1, MAD1L1, MAD2L1, BUB1B, BUB3, TTK, PLK1, AURKA, AURKB, TP53, and WEE1.
How does the spindle assembly checkpoint work?
The SAC monitors kinetochore-microtubule attachments and inhibits APC/C until all chromosomes are properly attached, preventing anaphase onset.
What happens when mitotic checkpoints fail?
Checkpoint failure leads to chromosomal instability, aneuploidy, and increased cancer risk.
Why is the G2/M checkpoint important in cancer therapy?
The G2/M checkpoint allows cells to repair DNA damage before mitosis; inhibiting it forces cells with damage into mitosis, causing mitotic catastrophe and enhancing radiation sensitivity.
Which diseases are linked to mitotic checkpoint defects?
Cancer, familial cancer predisposition, and chromosomal instability syndromes are linked to checkpoint defects.
How can I study mitotic checkpoint signaling in the lab?
Common methods include live-cell imaging, phosphoproteomics, CRISPR screens, flow cytometry, and yeast genetics.
What is the role of CHEK2 in checkpoint signaling?
CHEK2 is an effector kinase downstream of ATM that amplifies the DNA damage signal and regulates cell cycle arrest.
Can CRISPR be used to model checkpoint mutations?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to study checkpoint gene function.
What is synthetic lethality in the context of checkpoint inhibition?
Synthetic lethality occurs when a checkpoint inhibitor kills cells with a specific genetic defect while sparing normal cells, as seen in melanoma with G2-M checkpoint targeting.
Conclusion
GO:0007093 mitotic cell cycle checkpoint signaling is a fundamental biological process that safeguards genome integrity by coordinating DNA repair, replication, and chromosome segregation with cell cycle progression. Its dysregulation is central to cancer development, familial predisposition, and therapy resistance, making it a high-priority target for basic and translational research. Advances in CRISPR modeling, live-cell imaging, and functional genomics continue to illuminate the molecular mechanisms of checkpoint control and reveal new therapeutic opportunities.
References
- 1. Glaviano A et al.. 2025. Cell cycle dysregulation in cancer.. Pharmacol Rev 77(2):100030 PMID: 40148026
- 2. Jamasbi E et al.. 2022. The cell cycle, cancer development and therapy.. Mol Biol Rep 49(11):10875-10883 PMID: 35931874
- 3. Hauge S et al.. 2023. Expanding roles of cell cycle checkpoint inhibitors in radiation oncology.. Int J Radiat Biol 99(6):941-950 PMID: 33877959
- 4. Villarroya-Beltri C et al.. 2022. Mitotic Checkpoint Imbalances in Familial Cancer.. Cancer Res 82(19):3432-3434 PMID: 36193651
- 5. Yasutis KM et al.. 2013. Cell cycle checkpoint regulators reach a zillion.. Cell Cycle 12(10):1501-9 PMID: 23598718
- 6. Matellán L et al.. 2020. Regulation of Mitotic Exit by Cell Cycle Checkpoints: Lessons From Saccharomyces cerevisiae.. Genes (Basel) 11(2) PMID: 32059558
- 7. Zhou FY et al.. 2024. Prolonged cell cycle arrest in response to DNA damage in yeast requires the maintenance of DNA damage signaling and the spindle assembly checkpoint.. Elife 13 PMID: 39656839
- 8. Barnaba N et al.. 2021. Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma.. Cell Cycle 20(11):1041-1051 PMID: 33966611
